|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
The Immunogenicity of Therapeutic Proteins
Author(s)Fiona Adair, Daniel Ozanne
By Fiona Adair and Daniel Ozanne,Biovation Ltd., pp. 30-36. Immunogenicity is often a barrier to further development of potentially therapeutic proteins. That barrier often remains unknown until late in the development chain. The authors explore various strategies for preventing immunogenicity and for predicting it earlier in the process.
Advertisement
Articles in this issue
almost 24 years ago
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Baralmost 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementalmost 24 years ago
Analytical Advances: Calibration Management of Outsourced Calibrationsalmost 24 years ago
Inside Washington: Costs and Controls Challenge Manufacturersalmost 24 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
5

